Clinical Trial Update: Revumenib in Combination With 7+3 + Midostaurin in AML [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating Revumenib in combination with standard 7+3 chemotherapy and midostaurin for adult acute myeloid leukemia; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Gene Mutation

Drugs mentioned

• Cytarabine/Daunorubicin (7+3) (cytarabine and daunorubicin)
• Midostaurin (midostaurin)
• Revumenib (revumenib)

Snippet

Sponsor: Richard Stone, MD | Conditions: Acute Myeloid Leukemia, AML, Adult | Phase 1 | Status: RECRUITING